Loading...

SNTI SENTI BIOSCIENCES INC US FDA Inspections 8-K Filing

SNT

SNT

SENTI BIOSCIENCES INC

(SNTI)

2025 8-K

Summary

Summary

Financial Statements

Pre-Market Approval

Financial Statements

Clinical Data Announcement

Securities Offering

Financial Results

Board Appointment

Stockholder Votes

Management Change

Management Change

Clinical Trial Update

Clinical Data Release

Clinical Trial Update

Financial Results

Audit Committee Compliance

Sublease Agreement

Financial Update

Reverse Stock Split

Agreement Update

Amendment to Certificate of...

Management Change

Financial Results Announcement

Appointment of Officers

Costs Associated with Exit ...

FDA Clearance for SENTI-202

Financial Results Announcement

Collaboration Agreement

Financial Results Announcement

Delisting Notice

Entry into a Material Defin...

Annual Meeting of Stockholders

Financial Results Announcement

Resignation of Director

Financial Results Announcement

Strategic Plan Announcement

External Links:

On June 18, 2025, Senti Biosciences announced that the FDA granted Orphan Drug Designation to SENTI-202 for treating relapsed/refractory hematologic malignancies, including Acute Myeloid Leukemia. This designation could potentially accelerate the development of this treatment.

AI Assistant

SENTI BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.